Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One shot to smooth scars? new trial begins

NCT ID NCT07474467

Symptom relief Sponsor: CellinCells Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Aug 21, 2026 · Updated 4 times

Summary

This study tests a single injection of TRTP-101, a biological treatment, to see if it safely improves atrophic scars (like acne scars). Thirty-one adults will receive the injection on one side of their face and a placebo on the other, with neither they nor their doctors knowing which is which. The goal is to measure scar improvement and any side effects over several months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TRTP-101 (a biological injection)
What this could lead to
If it works, this could offer a new, one-time treatment to reduce the appearance of atrophic scars.
What could go wrong
This is an early, small trial (31 people) testing safety and effectiveness. The treatment may not work better than placebo, and there is a risk of side effects like skin reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 31 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Aug 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or Female aged greater than 19 years * Acne scars graded ≥ 3 on the 5-point ASRS \[Phase 1\] * Four or more atrophic scars in the joints, genitals, perineum, and face except for the lips, eyes and nose \[Phase 2\] * Atrophic scar lesions approximately 2 cm in diameter located on the cheeks or temple on both sides of the face * A response of "dissatisfied" or worse on the Subject Acne Scar Self-Assessment Scale Exclusion Criteria: * History of cell therapy * Treatment of Dermal resurfacing, Chemical/Mechanical Peel and Skin Photorejuvenation * Treatment of Hyaluronic acid/collagen skin filler, non-permanent soft tissue filler and fat grafting * Positive for virus infection * Use of Anticoagulant therapy or NSAIDs * Thrombocytopenia or other coagulation disorder * History of keloid scars * Infectious disease or other dermatitis in the area of the atrophic scar * Use of Immunosuppressant, immunomodulating drug, anticancer drug or radiation therapy * Use of systemic steroid medication * History of hypersensitivity or severe allergic reactions (e.g., anaphylaxis, Guillain-Barre syndrome, etc.) * Use of retinoid medications

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrophic scar are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrophic scar

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Samsung Medical Center

    RECRUITING

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.